Stemline Therapeutics Inc (NASDAQ:STML)‘s stock had its “buy” rating reissued by equities research analysts at Jefferies Group LLC in a research report issued to clients and investors on Thursday. They presently have a $16.00 target price on the biopharmaceutical company’s stock. Jefferies Group LLC’s price objective points to a potential upside of 89.35% from the company’s current price.

A number of other research analysts have also commented on the company. Zacks Investment Research raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 20th. HC Wainwright reissued a “buy” rating on shares of Stemline Therapeutics in a report on Monday, May 15th. Cowen and Company reissued a “buy” rating on shares of Stemline Therapeutics in a report on Friday, May 12th. Wedbush raised their price target on Stemline Therapeutics from $33.00 to $40.00 and gave the company an “outperform” rating in a report on Thursday, May 11th. Finally, Ladenburg Thalmann Financial Services set a $41.00 price target on Stemline Therapeutics and gave the company a “buy” rating in a report on Monday, March 20th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $29.17.

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Shares of Stemline Therapeutics (NASDAQ:STML) traded up 1.20% during trading on Thursday, hitting $8.45. 108,522 shares of the stock were exchanged. The firm has a 50 day moving average of $8.45 and a 200-day moving average of $9.76. Stemline Therapeutics has a 12-month low of $5.50 and a 12-month high of $14.60. The company’s market cap is $197.53 million.

Stemline Therapeutics (NASDAQ:STML) last issued its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.67) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.45) by $0.22. Stemline Therapeutics had a negative return on equity of 50.06% and a negative net margin of 4,058.44%. The company had revenue of $0.30 million during the quarter, compared to analyst estimates of $0.30 million. On average, analysts forecast that Stemline Therapeutics will post ($2.26) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.americanbankingnews.com/2017/05/27/jefferies-group-llc-reaffirms-buy-rating-for-stemline-therapeutics-inc-stml.html.

In related news, CEO Ivan Bergstein sold 17,980 shares of the stock in a transaction on Tuesday, February 28th. The stock was sold at an average price of $6.99, for a total value of $125,680.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Kenneth Hoberman sold 8,027 shares of the firm’s stock in a transaction dated Tuesday, February 28th. The stock was sold at an average price of $6.99, for a total value of $56,108.73. The disclosure for this sale can be found here. Insiders sold a total of 47,493 shares of company stock valued at $331,676 in the last quarter. 16.70% of the stock is currently owned by corporate insiders.

A number of large investors have recently made changes to their positions in the company. Nationwide Fund Advisors raised its stake in shares of Stemline Therapeutics by 7.8% in the first quarter. Nationwide Fund Advisors now owns 11,900 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 858 shares during the last quarter. Perceptive Advisors LLC acquired a new stake in shares of Stemline Therapeutics during the fourth quarter worth approximately $115,000. Wells Fargo & Company MN raised its stake in shares of Stemline Therapeutics by 3.8% in the first quarter. Wells Fargo & Company MN now owns 13,647 shares of the biopharmaceutical company’s stock worth $117,000 after buying an additional 500 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Stemline Therapeutics during the first quarter worth approximately $120,000. Finally, Ladenburg Thalmann Financial Services Inc. raised its stake in shares of Stemline Therapeutics by 810.6% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,694 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 11,300 shares during the last quarter. Hedge funds and other institutional investors own 37.76% of the company’s stock.

About Stemline Therapeutics

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

12 Month Chart for NASDAQ:STML

Receive News & Ratings for Stemline Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.